Triptorelin Pamoate (Trelstar®)

Common name: Triptorelin Pamoate
Brand name: Trelstar®
 

What is Triptorelin Pamoate?

Triptorelin is used in the palliative treatment of hormone dependent advanced prostate cancer. It works by reducing the amount testosterone in the blood.
 

How is Triptorelin Pamoate administered?

Triptorelin Pamoate is administered by intramuscular injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received triptorelin pamoate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast enlargement
  • Constipation
  • Diarrhea
  • Difficulty sleeping
  • Fatigue / weakness
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea
  • Reduced libido (low sex drive)

 
Is Triptorelin Pamoate covered in my province or territory?

Triptorelin pamoate is covered by provincial drug programs in:
  • New Brunswick
  • Newfoundland & Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Ontario
  • Quebec
  • Prince Edward Island
  • Yukon
Triptorelin pamoate is not covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • Saskatchewan
 
Last Reviewed: November 2013

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive